Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on November 9, 2016. The filing serves to report a material change pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant is a foreign private issuer based in Victoria, British Columbia.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing an external exhibit rather than a financial statement.
Material Changes
The primary material change reported is the execution of an At-The-Market (ATM) offering program, as detailed in Exhibit 99.1 (Material Change Report dated November 9, 2016). The filing incorporates this exhibit by reference into the company's Registration Statement on Form F-10 (File No. 333-206994).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. The document focuses solely on the administrative incorporation of the ATM exhibit.
Investor Verification Checklist
- Verify the specific terms and authorization limits of the ATM offering program in Exhibit 99.1.
- Review the Registration Statement on Form F-10 (File No. 333-206994) for the full context of the ATM program.
- Confirm the current status of the ATM program and any shares sold under this authorization in subsequent filings.